Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ABT-378/r

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2002
Review
2002
Despite major advances in HIV research, eradication of HIV from the body is not yet possible. However, current antiretroviral… Expand
2001
2001
  • TreatmentUpdate
  • 2001
  • Corpus ID: 28272217
On March 9, 2001, Health Canada granted permission to Abbott Laboratories for the sale of Kaletra (a combination of protease… Expand
2000
2000
Details and information sources on Kaletra (lopinavir plus low-dose ritonavir), a protease inhibitor approved last week. 
2000
2000
  • J. James
  • AIDS treatment news
  • 2000
  • Corpus ID: 8038028
Details and information sources on Kaletra (lopinavir plus low-dose ritonavir), a protease inhibitor approved last week. 
2000
2000
  • The AIDS reader
  • 2000
  • Corpus ID: 44625782
2000
2000
  • AIDS treatment news
  • 2000
  • Corpus ID: 42164108
Review
1999
Review
1999
  • AIDS treatment news
  • 1999
  • Corpus ID: 458713
The new protease inhibitor ABT-378/r, which is ABT-378 combined with a small amount of Ritonavir, is available to a limited… Expand
1999
1999
  • H. S. Bartnof
  • BETA : bulletin of experimental treatments for…
  • 1999
  • Corpus ID: 10290336
Several sessions at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) presented results of… Expand
1999
1999
  • L. J. Martinez
  • Research initiative, treatment action : RITA
  • 1999
  • Corpus ID: 9734640
Despite the promise of highly active antiretroviral therapies (HAART) to potentially suppress HIV, the ability of the virus to… Expand